Merrimack begins Phase I trial of MM-398 to treat brain cancer
Merrimack Pharmaceuticals has started enrolling patients in its Phase I clinical trial of MM-398 (nanoliposomal irinotecan injection) in a highly concentrated formulation to treat recurrent high grade glioma, a type of aggressive brain tumor with poo…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Clinical Trials | Glioma | Nanotechnology | Neurology | Pharmaceuticals